期刊文献+

普拉格雷中间体的合成研究 被引量:3

Synthesis of the intermediate of prasugrel
下载PDF
导出
摘要 目的探索制备普拉格雷合成重要中间体2-氟-α-环丙酰苄基溴的较优工艺条件。方法以邻氟溴苄为原料,经格氏反应和环丙基腈作用生成环丙基-2-氟苄基酮,再经α位溴化得到2-氟-α-环丙酰苄基溴。结果最佳配比为镁∶邻氟溴苄∶环丙基腈=1.1∶1∶0.8(摩尔比),洗脱液为石油醚∶乙酸乙酯=20∶1和15∶1(体积比),α-位溴化时用氢溴酸和过氧化氢代替液溴。结论改进后的合成方法工艺合理、可行,为工业化生产提供了实验依据。 Objective To synthesize the α-cyclopropylcarbonyl-2-fluorobenzyl bromide, which is an important intermediate for the synthesis of prasugrel, the optimum reaction conditions were explored by experiments. Methods Cyclopropyl 2-fluorobenzyl ketone was prepared starting from 2-fluorobenzyl bromide through Grignard reaction with eyelopropaneearbonitrile. Then α-cyclopropylcarbonyl-2-fluorobenzyl bromide was synthesized by the α-H of cyclopropyl 2-fluorobenzyl ketone being substituted by the atom of Br. Results The optimized matching conditions were Mg: 2-fluorobenzyl bromide: cyclopropanecarbonitrile = 1.1 : 1 : 0. 8 and the eluent was ligroin: acetic ether = 20:1 and 15: 1. The bromine,which was used for the substitution of α-H by the atom of Br was replaced by hydrobromic acid and hydrogen peroxide. Conclusions The upgraded process was rational and feasible, which could be used as experimental basis for mass production.
出处 《广东药学院学报》 CAS 2009年第3期272-274,共3页 Academic Journal of Guangdong College of Pharmacy
关键词 普拉格雷 邻氟溴苄 环丙基腈 环丙基-2-氟苄基酮 2-氟-α-环丙酰苄基溴 prasugrel 2-fluorobenzyl bromide cyclopropaneearbonitrile 2-fluorobenzyl ketone α-cyclopropylcarbonyl-2-fluorobenzyl bromide
  • 相关文献

参考文献7

二级参考文献45

  • 1路新华,郑智慧,马瑛,石英,董悦生,任晓,穆栋,张华,贺建功.微生物来源的Xa因子抑制剂F02-2172的研究[J].中国抗生素杂志,2007,32(5):277-279. 被引量:9
  • 2陈新谦 金有豫.新编药物学[M].北京:人民卫生出版社,1997.535.
  • 3European Medicines Agency. European Public Assessment Report (EPAR) Xarelto, EMEA/H/C/944 [ EB/OL ]. [ 2008 - 10 - 11 ]. http://www. emea. europa. eu/humandoes/PDFs/EPAR/xareho/H-94-en1. pdf
  • 4European Medicines Agency. European Public Assessment Report (EPAR) Xarelto, EMEA/H/C/944 [ EB/OL ]. [ 2008 - 10 - 11 ]., http://www. emea. europa, eu/humandocs/Humans/EPAR/xarelto/xarelto. htm.
  • 5ROEHRIG S, STRAUB A, POHLMANN J. Discovery of the novel antithrombotic agent 5 -chloro-N- ( │( 5 S ) -2-ox0-3 - [ 4- ( 3 -oxomorpholin-4-yl) phenyl ] -1,3-oxazolidin-5-yl │ methyl ) thiophene- 2-carboxamide (BAY 59-7939) : an oral, direct factor Xa inhibitor[ J]. J Med Chem,2005,48 ( 19 ) :5900 - 5908.
  • 6DAURE EW, FUJIKAWA K, KISIEL W. The coagulation cascude: Initiation, maintenance and regulation [ J ]. Biochemistry, 1991,30(43) :10363 - 10370.
  • 7WEINZ C, BUETEHORN U,DAEHLER HP, et al. Pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in rats and dogs [ J ]. Xenobiotica, 2005,35 ( 9 ) : 891 -910
  • 8KUBITZA D, BECKA M, ZUEHLSDOR M, et al. Effect of Food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (Rivaroxaban) , an oral, direct factor Xa inhibitor, in healthy subjects [ J ]. J Clin Pharm, 2006,46 ( 6 ) : 549 - 558.
  • 9LASSEN MR, TUPRPIE AG, ROSENCHER N, et al. Rivaroxaban an oral, direct factor Xa inhibitor for thromboprophylaxis after totalknee arthroplasty: The RECORD3 Trial. (Abstract No.308). American Society of Hematology. 49th Annual Meeting. Atlanta. December 2007 [ EB/OL]. [ 2007 - 11 - 16 ]. http:// www. abstracts2view. com/hem07/view. php? nu = HEM07L1-2447.
  • 10Pivotal phase III data showed rivaroxaban was statistically superior to enoxaparin in preventing venous thromboembolism (VTE) in patients following hip replacement surgery. NewYork: BusinessWire[ EB/OL]. [ 2007 - 12 -08 ]. http ://proquest. umi. com/ pqdweb? did = 1395271941&sid = 1&Fmt = 7&clientld = 26489&RQT = 309&VName = PQD.

共引文献56

同被引文献30

  • 1王国平,侯建,孙志国.用于制备普拉格雷中间体及其制备方法[P].CN:200810202545.5,2009-04-08.
  • 2吴雪松,岑均达,郭珩.制备普拉格雷的中间体及其制备方法[P].CN101245072A,2008.
  • 3Baker W L,White C M. Role of prasugrel,a novel P2Y(12)re- ceptor antagonist, in the management of acute coronary syn- dromes[J]. Am J Cardiovase Drugs,2009,9(4) :213- 229.
  • 4Farid N A,Smith R L,Gillespie T A,et al. The disposition of prasugrel,a novel thienopyridine in humans[J]. Drug Metab Dispos, 2007,35 ( 7 ) : 1096-1104.
  • 5Farid N A,Kurihara A,Wrighton S A. Metabolism and dispo- sition of the thienopyridine antiplatelet drugs ticlopidine clopi- dogrel and prasugrel in humans[J]. J Clin Pharm,2010,50(2) : 126-142.
  • 6Asai F, Jakubowski J A, Naganuma H, et al. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A single ascending dose study in healthy humans[J]. Platelets,2006,17(4) : 209-217.
  • 7Jakunowski J A,Winters K J, Naganuma H, et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct an- tiplatelet profile[J]. Cardiovascular Drug Rev, 2007, 25 (4) : 354-374.
  • 8Asai F, Ogawa T, Naganuma H, et al. Maleateaddition salt of hydropyridine derivatives : EP, 728794[P]. 2006-12-06.
  • 9Ataka K, Miyata H, Kohno M, et al. 2-Silyloxy-tetrahydrothien- opyridine,salt thereof and process forpreparing the same:US, 5874581[P]. 1997- 02 -23.
  • 10Jakubowski JA, WinterINTER K J, Naganuma H, eta|. Prasugrel: Aa novel thienopyridine antiplatelet a-gent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile [ J ]. Cardiovascular Drug Rev ,2007 ,25 (4) :357 - 374.

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部